Cardiomyopathy protection in Chagas Disease - World Journal of Cardiovascular Diseases

WJCD > Vol.3 No.7, October 2013

Cardiomyopathy protection in Chagas Disease ()

HTML

Download as PDF (Size: 66KB) PP. 442-447

DOI: 10.4236/wjcd.2013.37069 5,014 Downloads 6,966 Views Citations

Author(s)

Jorge E. Mitelman, Luisa Gimenez

Affiliation(s)

Instituto Centenario, Buenos Aires, Argentine Chagas Disease of the Inter-American Society of Cardiology, Buenos Aires, Argentine Department of Chagas, the University Institute of Health Science Foundation H A Barcelo, Buenos Aires, Argentine.
Teodoro Alvarez Hospital, Buenos Aires, Argentine Cardiology in Northern Province of Buenos Aires, Buenos Aires, Argentine Chagas in the City of Buenos Aires, Buenos Aires, Argentine University Institute of Health Science Foundation H A Barcelo, Buenos Aires, Argentine.

ABSTRACT

There is some published evidence suggesting micro vascular endothelial dysfunction and dysautonomia involvement in Chagas disease in association with cardiomyocyte changes favoring disease progression. The combined treatment between angiotensin converting enzyme (ACE) inhibitor drugs; Simvastatin, muscarinic antibody immunoadsorbent together with fungicidal drugs would open therapeutic possibilities in this disease.

KEYWORDS

Chagas Disease; Chronic Period without Demonstrable Pathology; Ex Indeterminate Phase; Endothelial Dysfunction; Cardiac Dysautonomia; Simvastatin; ACE (Angiotensin Converting Enzyme) Inhibitor; Muscarinic Antibody

Share and Cite:

Mitelman, J. and Gimenez, L. (2013) Cardiomyopathy protection in Chagas Disease. World Journal of Cardiovascular Diseases, 3, 442-447. doi: 10.4236/wjcd.2013.37069.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies